Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa Sells 8,879 Shares

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa sold 8,879 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total value of $205,104.90. Following the transaction, the chief financial officer now owns 23,382 shares in the company, valued at approximately $540,124.20. This trade represents a 27.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Mark Ragosa also recently made the following trade(s):

• On Monday, March 17th, Mark Ragosa sold 11,464 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $23.10, for a total value of $264,818.40.
• On Wednesday, March 12th, Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $22.25, for a total value of $809,277.00.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA stock opened at $23.81 on Friday. The stock’s fifty day moving average price is $20.23 and its two-hundred day moving average price is $22.09. The company has a market cap of $1.73 billion, a PE ratio of -170.06 and a beta of 0.48. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $16.56 and a fifty-two week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The business had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company’s revenue for the quarter was up 46.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.35 EPS. On average, equities analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Large investors have recently modified their holdings of the business. Quarry LP acquired a new stake in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at $50,000. Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals during the 4th quarter valued at $61,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter valued at $189,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Kiniksa Pharmaceuticals during the 4th quarter valued at $158,000. Finally, Bellevue Group AG acquired a new stake in shares of Kiniksa Pharmaceuticals during the 4th quarter valued at $160,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Wall Street Analysts Forecast Growth

KNSA has been the topic of a number of recent research reports. Wedbush restated an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $37.17.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.